Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently emerged as a highly virulent respiratory pathogen that is known as the causative agent of coronavirus disease 2019 (COVID-19). Diarrhea is a common early symptom in a significant proportion of patients with SARS-CoV-2 infection. SARS-CoV-2 can infect and replicate in esophageal cells and enterocytes, leading to direct damage to the intestinal epithelium. The infection decreases the level of angiotensin-converting enzyme 2 receptors, thereby altering the composition of the gut microbiota. SARS-CoV-2 elicits a cytokine storm, which contributes to gastrointestinal inflammation. The direct cytopathic effects of SARS-CoV-2, gut dysbiosis, and aberrant immune response result in increased intestinal permeability, which may exacerbate existing symptoms and worsen the prognosis. By exploring the elements of pathogenesis, several therapeutic options have emerged for the treatment of COVID-19 patients, such as biologics and biotherapeutic agents. However, the presence of SARS-CoV-2 in the feces may facilitate the spread of COVID-19 through fecal-oral transmission and contaminate the environment. Thus gastrointestinal SARS-CoV-2 infection has important epidemiological significance. The development of new therapeutic and preventive options is necessary to treat and restrict the spread of this severe and widespread infection more effectively. Therefore, we summarize the key elements involved in the pathogenesis and the epidemiology of COVID-19-associated diarrhea.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218355 | PMC |
| http://dx.doi.org/10.3748/wjg.v27.i23.3208 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
Lancet Infect Dis
January 2025
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address:
Article Synopsis
- The study follows the PANORAMIC trial, investigating the long-term effectiveness of molnupiravir for COVID-19 on wellbeing, persistent symptoms, new infections, healthcare use, and time off work at 3 and 6 months post-randomization.
- Participants included adults over 50 or younger with specific health issues, who were affected by COVID-19 for less than 5 days and were divided into either a molnupiravir treatment group or a standard care group.
- The trial involved 25,783 participants and aimed to assess various secondary outcomes, including self-reported wellness, symptom severity, health-related quality of life, and overall healthcare usage after the initial
Fecal microbiota transplantation alleviates mild-moderate COVID-19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double-blind clinical trial.
J Med Virol
August 2024
Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Article Synopsis
- The study investigates the effectiveness of fecal microbiota transplantation (FMT) in treating mild to moderate COVID-19 symptoms in a cohort of 40 patients.
- Results indicate that FMT significantly improved digestive symptoms like diarrhea and neuropsychiatric issues such as depression, with notable reductions in symptom severity compared to a placebo group.
- Additionally, FMT was associated with a decrease in a biomarker related to long COVID-19, suggesting it could be a promising treatment strategy for managing lingering symptoms in COVID-19 patients.
Severe Refractory Diarrhea Associated with COVID-19: A Case Report.
Case Rep Gastroenterol
June 2024
Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan.
Article Synopsis
- COVID-19, caused by SARS-CoV-2, can lead to gastrointestinal issues like severe diarrhea, which may persist even after recovery from the virus.
- A 50-year-old man with COVID-19 pneumonia developed refractory diarrhea that reached alarming volumes, leading to further medical intervention and treatment for a suspected enterocolitis linked to the virus.
- Administering methylprednisolone significantly improved the patient's condition, suggesting that corticosteroids may be beneficial for post-COVID-19 patients experiencing severe diarrhea due to abnormal immune responses.
A rare twist: COVID-19 infection masquerading as IgA vasculitis in a hemophilia a patient.
Clin Rheumatol
April 2024
Department of Anatomical Pathology, PureLab, Abu Dhabi, United Arab Emirates.
Hemophilia A and B are one of the most common hereditary bleeding disorders. Patients are predisposed to bleeding spontaneously or after minor trauma in different areas such as the skin, gastrointestinal, or joints. COVID-19 infection has been associated with various clinical manifestations and complications including rarely triggering IgA vasculitis.
View Article and Find Full Text PDFInsights into parasites and COVID-19 co-infections in Iran: a systematic review.
Trans R Soc Trop Med Hyg
June 2024
Zoonoses Research Center, Ardabil University of Medical Sciences, Ardabil 56189-53141, Iran.
Background: It is well-documented that using immunosuppressive drugs such as corticosteroids or cytokine blockers in treating coronavirus disease 2019 (COVID-19) increases the risk of co-infections. Here we systematically summarized the cases of COVID-19-associated parasitic infections (CAPIs) in Iran.
Methods: From 19 February 2020 to 10 May 2023, all studies on Iranian patients suffering from CAPIs were collected from several databases using a systematic search strategy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!